Citation Tools

Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial

Download to a citation manager

Cite this article as:
Dakin HA, Wordsworth S, Rogers CA, et al
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial